Skyrizi®
Drug class
- Biologic/biosimilar
- IL-23 inhibitor
Generic name
Risankizumab-rzaa
Safety
Efficacy
Convenience
Indications
Approved for moderate to severe Crohn's disease and moderate to severe ulcerative colitis.
How it works
By inhibiting specific proteins that cause inflammation, biologic medications reduce disease activity and severity.
Drug interactions
Do not use live vaccines while using this medication.
Pre-treatment screening tests
Liver enzymes and bilirubin levels, age-appropriate vaccinations, tuberculosis, hepatitis panel.
Tests during screening
Liver enzymes and bilirubin levels, age-appropriate vaccinations, tuberculosis, and hepatitis panel.
Route of administration
Frequency
First maintenance dose starts at week 12, and then 1 dose every 8 weeks
Side effects
Upper respiratory infections (flu or colds), headache, joint pain, stomach pain, injection site reactions, anemia, fever, back pain, urinary tract infection.
Contraindications
Serious hypersensitivity to risankizumab or any component of the formulation.
Safety information
Symptoms of serious allergic reaction, like face swelling, fainting, dizziness, hives, shortness of breath. May increase risk of infection. Symptoms of infections (e.g., fever, cough, etc.) and headache, gastroenteritis, diarrhea, and fatigue.